Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19

Br J Pharmacol. 2021 Oct;178(19):3864-3868. doi: 10.1111/bph.15579. Epub 2021 Jun 24.

Abstract

Sepsis induced by bacteria or viruses can result in multiorgan dysfunction, which is a major cause of death in intensive care units. Current treatments are only supportive, and there are no treatments that reverse the pathophysiological effects of sepsis. Vitamin C has antioxidant, anti-inflammatory, anticoagulant and immune modulatory actions, so it is a rational treatment for sepsis. Here, we summarise data that support the use of megadose vitamin C as a treatment for sepsis and COVID-19. Megadose intravenous sodium ascorbate (150 g per 40 kg over 7 h) dramatically improved the clinical state and cardiovascular, pulmonary, hepatic and renal function and decreased body temperature, in a clinically relevant ovine model of Gram-negative bacteria-induced sepsis. In a critically ill COVID-19 patient, intravenous sodium ascorbate (60 g) restored arterial pressure, improved renal function and increased arterial blood oxygen levels. These findings suggest that megadose vitamin C should be trialled as a treatment for sepsis and COVID-19.

Keywords: COVID-19; acute kidney injury; hypotension; hypoxia; inflammation; oxidative stress; sepsis; sodium ascorbate; vitamin C.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Ascorbic Acid
  • COVID-19*
  • Humans
  • Multiple Organ Failure / drug therapy
  • SARS-CoV-2
  • Sepsis* / drug therapy
  • Sheep

Substances

  • Ascorbic Acid